Slow-moving regulators have kept the rules of engagement on social media platforms fuzzy for pharma players. Yet rather than sit on the sidelines waiting for the FDA to take a firm stance on dos and don'ts, many pharma companies have taken a shot at safe moves in the social realm. Potentially powerful collaboration tools have also attracted pharma groups, bringing scientists, patients and physicians into the same digital arenas to share ideas and partner on research. Read the report >>
Martin Leach has spent the past several months building a new data sciences group at Biogen Idec, where his team of informatics and tech pros has undertaken the sizable task of enabling scientists and others at the biotech powerhouse to make use of Big Data.
Two of my senior colleagues and I are headed to Boston this week for the Bio-IT World Expo in Boston. I'll be posting breaking news from the show as well as interviews with some of the top minds in bioinformatics, clinical IT and discovery software.
GlaxoSmithKline has launched a study in the U.K. that would test its experimental drug called fluticasone furoate/vilanterol (Breo/Relvar), to investigate the potential blockbuster outside of a traditional clinical trial, in a way that simulates how patients with smoker's cough and asthma would take it in the real world. It's a big deal.
Behind the huge and scary numbers that accompany the costs of drug development, there are various holes and dysfunctional practices in the process of bringing a new drug to market.
From what I've seen, the pharma fleet hasn't taken flight with many new uses of social media to ease some of the most acute problems in the industry.
These apps show just how broad and innovative the life science mobile world has become. Yet each is trying to solve the same critical problem--how can we make drug development more efficient? Here we present 15 mobile apps that tried to answer that question in 2012. Click here to view this slideshow >>
Call it the bionic drug R&D group. Without scads of scientists on hand, AstraZeneca's virtual neuroscience unit relies heavily on information technologies to automate some of the heavy lifting of managing a pipeline of drugs for neurological and psychiatric disorders. In an interview with FierceBiotech IT, AZ research information head John Reynders described the tech platforms supporting the research group.